Within 2 years we will have proof of concept data with RC220 from the fully funded Phase 1a/b Trial, for both cardio protection and anti-cancer synergy. In fact, we can expect to receive updates well before trial completion. We will know whether bisantrene works soon enough.
I don’t think we’ll get bought out until after we have some Phase 2 data under our belts, but imo there’s no likely scenario where our SP is anywhere near this range come 2026 (for better or worse).
I’m not sure where you got ~9 years from. It’s never been Race’s goal to take bisantrene all the way to market.
I’d suggest freshening up on the November 2023 Strategic update.
- Forums
- ASX - By Stock
- RAC
- Ann: Quarterly Activity Report & Appendix 4C
Ann: Quarterly Activity Report & Appendix 4C, page-105
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.040(2.20%) |
Mkt cap ! $302.5M |
Open | High | Low | Value | Volume |
$1.81 | $1.82 | $1.76 | $132.8K | 74.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 170 | $1.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.78 | 2 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 1.755 |
3 | 12714 | 1.750 |
1 | 3000 | 1.740 |
1 | 1405 | 1.720 |
4 | 25414 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.780 | 3781 | 1 |
1.830 | 7500 | 1 |
1.840 | 1000 | 1 |
1.850 | 5222 | 1 |
1.880 | 2351 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |